Pacific Channel releases updated internal analysis of LCT 10/09/2019, page-36

What was needed was wiser and more experienced help in designing the trial for human implants in Parkinsons disease. Paying for advice or even clinical expertise from one of the more successful US surgical researchers would have probably avoided the current problems. They've been through all this before and know the problems. But then so did Barry Snow I would guess.

I can't see a commercial director can contribute anything over and above what Ken Taylor is capable of. Unless you are going to go back to the "stem cell clinic" idea. IMO that's a complete non starter. Scientifically run stem cell research doesn't require Immupel, unless your suggesting xeno-transplantation of stem cells. But then how would that possibly work when the stem cells grow? Its nonsense.